Intralesional Methotrexate for the Treatment of Keratoacanthoma: Retrospective Study and Review of the Korean Literature
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoo, Min Gun | - |
dc.contributor.author | Kim, Il-Hwan | - |
dc.date.accessioned | 2021-09-05T10:04:36Z | - |
dc.date.available | 2021-09-05T10:04:36Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-04 | - |
dc.identifier.issn | 1013-9087 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/98850 | - |
dc.description.abstract | Background: Although intralesional methotrexate (MTX) is an effective, nonsurgical treatment of keratoacanthoma (KA), there have not been many reports of on the MTX treatment for KA in Korea. Objective: The purpose of this study was to evaluate the clinical efficacy of the intralesional MTX for the treatment of KA in Korean patients. Methods: We retrospectively studied seven patients with KA who received intralesional injection of MTX in our department. The efficacy was evaluated based on the physician assessment. Our review also included the cases of KA treated with intralesional MTX in Korean patients from the previous reports. We then analyzed the therapeutic regimens in the Korean patients by comparing them with the Caucasian patients. Results: We identified 11 cases of Korean KA patients treated with an intralesional MTX, including seven from our institution and four from the Korean literature. Ten of the 11 patients (91%) showed a complete resolution with an intralesional MTX. No adverse events were observed during the treatment and the follow-up periods. No recurrence was found during the follow-up. In therapeutic analysis, the Korean patients required 2 to 7 injections (mean 4.6 injections) to achieve a tumor resolution with the mean time to clearing at 7.6 weeks. Conclusion: Intralesional MTX can be an effective and safe non-operative treatment modality for most Koreans with KA. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN DERMATOLOGICAL ASSOC | - |
dc.title | Intralesional Methotrexate for the Treatment of Keratoacanthoma: Retrospective Study and Review of the Korean Literature | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Il-Hwan | - |
dc.identifier.doi | 10.5021/ad.2014.26.2.172 | - |
dc.identifier.scopusid | 2-s2.0-84901817023 | - |
dc.identifier.wosid | 000336344300005 | - |
dc.identifier.bibliographicCitation | ANNALS OF DERMATOLOGY, v.26, no.2, pp.172 - 176 | - |
dc.relation.isPartOf | ANNALS OF DERMATOLOGY | - |
dc.citation.title | ANNALS OF DERMATOLOGY | - |
dc.citation.volume | 26 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 172 | - |
dc.citation.endPage | 176 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART001872128 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Dermatology | - |
dc.relation.journalWebOfScienceCategory | Dermatology | - |
dc.subject.keywordAuthor | Intralesional injection | - |
dc.subject.keywordAuthor | Keratoacanthoma | - |
dc.subject.keywordAuthor | Koreans | - |
dc.subject.keywordAuthor | Methotrexate | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.